Frequently Asked Questions
In 2022, the global Small Molecule Drug Discovery Market is expected to be worth USD 47218.9 million.
The Small Molecule Drug Discovery Market is estimated to increase at a CAGR of 8.60% between 2023 and 2030, reaching USD 47218.9Million in 2030.
During the forecast period, the oncology segment is likely to lead the market
High-Throughput Screening (HTS) dominates the market
Small Organic Molecules has the highest CAGR in the Small Molecule Drug Discovery business
North America is expected to dominate the market in 2022, accounting for 40% of total revenue.
The top players include Merck & Co., Inc., Pfizer Inc., Bayer AG, GlaxoSmithKline Plc., Daiichi Sanky21st Century Therapeutics Inc., 4SC AG.
The rising frequency of chronic illnesses is fueling demand for small molecule medications. Technological advances in drug discovery approaches, such as high-throughput screening and computer-aided drug design and development, have resulted in Pharmaceutical firms’ increasing investment in R&D operations is one of the market’s main drivers.
For novel medication development, there are stringent regulatory criteria and long approval processes. The high expense of medication discovery and development, including clinical trials and manufacturing, The market’s main obstacles include potential side effects and safety issues connected with small molecule medications.
The significant opportunities in the market include rising demand for personalized medicine and targeted medicines, increasing acceptance of artificial intelligence and machine learning in drug development, and expanding market potential in emerging nations with improving healthcare infrastructure.